PT INDOFARMA TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 204 IDR | -1.92% |
|
-29.17% | -64.83% |
| 2023 | PT Indofarma Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| 2023 | PT Indofarma Tbk Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 2,902B 180M | Sales 2022 | 1,144B 70.93M | Capitalization | 3,564B 221M |
|---|---|---|---|---|---|
| Net income 2021 | -37.58B -2.33M | Net income 2022 | -428B -26.56M | EV / Sales 2021 | 2.46 x |
| Net Debt 2021 | 224B 13.89M | Net Debt 2022 | 357B 22.16M | EV / Sales 2022 | 3.43 x |
| P/E ratio 2021 |
-184
x | P/E ratio 2022 |
-8.32
x | Employees | 1,086 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 11.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.92% | ||
| 1 week | -29.17% | ||
| 1 month | +52.24% | ||
| 3 months | -47.42% | ||
| 6 months | -59.04% | ||
| Current year | -64.83% |
1 week
204.00
272.00
1 month
135.00288.00
Current year
130.00595.00
1 year
130.00725.00
3 years
130.003 490.00
5 years
130.007 350.00
10 years
120.007 350.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 23-01-29 | |
| Director of Finance/CFO | 57 | 22-05-30 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Teddy Wibisana
BRD | Director/Board Member | 57 | 15-04-07 |
| Director/Board Member | 63 | 20-07-28 | |
| Chairman | 62 | 21-05-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 204 | -1.92% | 111,700 |
| 24-05-30 | 208 | -9.57% | 74,600 |
| 24-05-29 | 230 | -9.45% | 122,300 |
| 24-05-28 | 254 | -9.29% | 77,900 |
End-of-day quote INDONESIA S.E., May 30, 2024
More quotes
PT Indofarma Tbk is an Indonesia-based company, which is engaged in the healthcare industry. The Company's business segment based on the products consists of the drug business segment and other medical equipment segment. The medical equipment segment consists of diagnostic and medical equipment. Its business segment based on geographical distribution area covers five regions consisting of Sumatra, Java, Kalimantan, Sulawesi and Bali, West Nusa Tenggara, and East Indonesia. Its products and services include generic drugs, over-the-counter and food, medical devices, non-medical devices and household health products. The Company carries out business activities to produce either alone or under cooperation for finished drug products, such as essential medicines, generic medicines with logos, generic medicines with trade names, traditional medicines, medical equipment, diagnostics, as well as food products, both related to health maintenance and improvement as well as health restoration.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -64.83% | 38.92M | |
| +40.73% | 739B | |
| +31.13% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +14.99% | 240B | |
| +9.26% | 210B | |
| -5.24% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- INAF Stock
